The trading price of Standard BioTools Inc (NASDAQ:LAB) closed lower on Tuesday, April 02, closing at $2.64, -2.22% lower than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $3.16 and a 52-week low of $1.46. Over the past month, the stock has gained 5.60% in value.
Standard BioTools Inc, whose market valuation is $765.92 million at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $0 per share this quarter, however they have predicted annual earnings per share of -$0.01 for 2024 and $0 for 2025.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Standard BioTools Inc No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest LAB has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 50% Buy.
A quick review shows that LAB’s price is currently -0.58% off the SMA20 and 5.95% off the SMA50. The RSI metric on the 14-day chart is currently showing 53.08, and weekly volatility stands at 4.78%. When measured over the past 30 days, the indicator reaches 5.42%. Standard BioTools Inc (NASDAQ:LAB)’s beta value is currently sitting at 1.64, while the Average True Range indicator is currently displaying 0.14.
To see how Standard BioTools Inc stock has been performing in comparison to its peers in the industry, here are the numbers: LAB stock’s performance was -2.22% in the latest trading, and 32.66% in the past year.
An evaluation of the daily trading volume of Standard BioTools Inc (NASDAQ:LAB) indicates that the 3-month average is 1.90 million. However, this figure has increased over the past 10 days to an average of 2.0 million.
Currently, records show that 290.12 million of the company’s shares remain outstanding. The insiders hold 2.56% of outstanding shares, whereas institutions hold 63.79%. The stats also highlight that short interest as of Mar 15, 2024, stood at 9.26 million shares, resulting in a short ratio of 4.91 at that time. From this, we can conclude that short interest is 3.19% of the company’s total outstanding shares. It is noteworthy that short shares in March were up slightly from the previous month’s figure, which was 8.06 million. However, since the stock’s price has seen 19.46% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
